106 articles in this category. All content is educational and for research purposes only.
5-Amino-1MQ research profile: how NNMT inhibition works, what the mouse studies show, why no human data exist, and platform pricing across 62 suppliers.
7 min readAbarelix (Plenaxis) was the first GnRH receptor antagonist approved by the FDA, establishing the pharmacological foundation for modern androgen deprivation…
10 min readAMG133 (MariTide) is a bispecific antibody-peptide conjugate combining GIPR antagonism with GLP-1 agonism, achieving ~20% average weight loss at 52 weeks with once-monthly dosing in Phase 2 trials.
11 min readResearch profile of amycretin, Novo Nordisk's investigational unimolecular GLP-1 and amylin receptor co-agonist available in oral and subcutaneous forms. Covers mechanism, Phase 1 oral data (13.1% weight loss at 12 weeks), Phase 1b/2a subcutaneous results (Lancet 2025), and how it differs from CagriSema.
11 min readAOD-9604 (HGH fragment 176-191) activates β3-adrenergic lipolysis without IGF-1 effects. Research profile: mechanism, cartilage data, and pricing.
3 min readAOD-9604 was designed to isolate the fat-metabolizing domain of human growth hormone without its growth or glucose effects. This profile reviews the preclinical lipolysis data, the Phase I–II clinical outcome that ended the obesity program, and the compound’s later musculoskeletal research.
13 min readComplete research profile for ARA-290 (cibinetide) — an erythropoietin-derived peptide targeting the innate repair receptor for neuropathic pain and tissue protection research.